Understand the source comparison
Peptide Stacking Guide: Combination Comparison
The table below compares documented peptide stack combinations by receptor target, mechanism, half-life coordination, and documented synergy evidence. Use this to assess whether a proposed stack introduces complementary pathways or redundant receptor saturatio
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares documented peptide stack combinations by receptor target, mechanism, half-life coordination, and documented synergy evidence. Use this to assess whether a proposed stack introduces complementary pathways or redundant receptor saturation.
- Ipamorelin + CJC-1295 No DAC
- None. GHSR-1a vs GHRH-R
- Complementary. GHRP triggers pulse, GHRH amplifies
- Both short-acting, dosed together
- Yes. 1.5–3× GH release vs monotherapy (JCEM 2006)
- Gold standard GH stack
- BPC-157 + TB-500
- None. VEGF/NO pathways vs actin binding
- Complementary. Signaling vs cytoskeleton
- BPC 2x/day, TB-500 1–2x/week
- Yes. Rodent tendon models show faster repair
- Best-documented tissue repair stack
- Tesamorelin + Ipamorelin
- None. GHRH-R vs GHSR-1a
- Complementary. Both trigger pulsatile GH
- Yes. Pulsatile GH synergy demonstrated
- Clean short-acting GH pulse stack
- AOD9604 + Tesamorelin
- None. Beta-3 adrenergic vs GHRH-R
- Complementary. Direct lipolysis vs GH-mediated fat loss
- AOD daily, Tesamorelin daily evening
- Limited clinical data, mechanistically sound
- Mechanistically valid metabolic stack
- Semax + Selank
- None. BDNF pathways vs GABAergic modulation
- Complementary. Neuroplasticity vs anxiolytic
- Both short-acting, dosed 1–2x/day
- Limited, primarily rodent models
- Mechanistically distinct cognitive stack
- GHRP-2 + GHRP-6
- High. Both bind GHSR-1a
- Redundant. Competitive receptor binding
- Both short-acting, but compete
- No. Competitive inhibition reduces efficiency
- Avoid. Receptor saturation with no benefit
- Tirzepatide + Semaglutide
- High. Both activate GLP-1R
- Redundant. Tirzepatide already activates GLP-1R
- Tirzepatide weekly, Semaglutide weekly
- No. Competitive GLP-1R binding
- Avoid. Redundant GLP-1 pathway activation
- MK-677 + Ipamorelin
- High. Both activate GHSR-1a
- Redundant. Both are ghrelin mimetics
- MK-677 oral 24h, Ipamorelin 2h
- No. MK-677 saturates receptors Ipamorelin would bind
- Avoid. Use MK-677 with GHRH analog, not GHRP